1. Signaling Pathways
  2. Cell Cycle/DNA Damage
    Metabolic Enzyme/Protease
  3. TLK

TLK 

Tousled-like kinase

TLKs are implicated in DNA replication, DNA repair, transcription, chromatin structure, viral latency, cell cycle checkpoint control and chromosomal stability in various organisms. Both TLK1 and TLK2 are frequently amplified in human cancers and TLK2 mutations have been identified in patients with neurodevelopmental disorders characterized by intellectual disability (ID), autism spectrum disorder (ASD) and microcephaly.

TLK 相关产品 (3):

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-162426
    UNC-CA2-103 Inhibitor 99.26%
    UNC-CA2-103 是一种 TLK2 抑制剂,对人源 IC50 为 18 nM,且相对于 TLK1 和绝大多数其他激酶具有高选择性UNC-CA2-103 可用于乳腺癌、胶质母细胞瘤、胃癌的相关研究
    UNC-CA2-103
  • HY-149213
    LSD1/TLK1-IN-1 Inhibitor 99.20%
    LSD1/TLK1-IN-1 是一种具有口服活性的 LSD1TLK1TLK2TTK 抑制剂,其 LSD1 IC50 为 0.247 μM。LSD1/TLK1-IN-1 可抑制 Nek1 于 T141 位点、Rad9 于 S328 位点的磷酸化,阻断 TLK1>Nek1>ATR>Chk1 信号轴,保护 H3K4me1/2 不被去甲基化,且对 LSD2MAO-AMAO-B 无影响。LSD1/TLK1-IN-1 可诱导细胞凋亡、绕过细胞周期阻滞、抑制肿瘤生长,同时可作为弱效 D4R 拮抗剂,下调 PD-L1 表达、增强 T 细胞杀伤反应、抑制胃癌细胞增殖,且毒性极低,对正常前列腺细胞无显著作用。LSD1/TLK1-IN-1 可用于前列腺癌与胃癌相关的研究。
    LSD1/TLK1-IN-1
  • HY-173186
    TLK1-IN-1 Inhibitor
    TLK1-IN-1 (Compound 5n) 是一种 TLK1 抑制剂,对 TLK1BIC50 为 7.2 μM ,对 LNCaP 细胞的 GI50 为 2.7 μM。TLK1-IN-1 诱导癌细胞 DNA 损伤和凋亡 (Apoptosis),可用于前列腺癌领域的研究。
    TLK1-IN-1